September 9, 2014
Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.
July 8, 2015
…Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, associate…
June 1, 2018
…a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.
March 9, 2018
…grant from the state’s stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target…
March 7, 2023
UC San Diego researchers delve deep into the unknown cause of pediatric acute myeloid leukemia to identify a gene splicing dysregulation and potential target for treating the disease, which often becomes treatment-resistant.
June 11, 2020
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
July 20, 2017
…researchers to develop a new immunotherapy in which patients’ cells would be equipped with a special receptor that recognizes and targets cancer stem cells, whose survival abilities often render standard therapies ineffective or short-term.
February 16, 2023
UC San Diego researchers report that a late-stage, pre-clinical small molecule inhibitor reverses malignant hyper-editing by a protein that promotes silencing of the immune response, metastasis and therapeutic resistance in 20 different cancer types.
January 26, 2021
Viral infections and space travel similarly trigger inflammation and the enzymes APOBEC3C and ADAR1; UC San Diego researchers are developing ways to inhibit them as a means to potentially lower cancer risk for both astronauts and people on Earth.
August 12, 2021
UC San Diego researchers develop a method to grow hematopoietic stem cells in culture, with clinical implications for bone marrow transplants and aging research.
